Hosted on MSN1mon
Leerink raises 89bio stock target to $37 on NASH study optimism(NASDAQ:ETNB) to $37 from $34, while reiterating an Outperform ... data from a Phase 2b SYMMETRY study of efruxifermin (EFX) in NASH patients with compensated cirrhosis. The results demonstrated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results